Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1994 1
1995 1
1996 1
1998 2
1999 1
2000 3
2001 1
2002 3
2003 3
2004 1
2005 2
2006 1
2007 1
2011 1
2013 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Among authors: daifotis ag. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
Risks to the 340B Drug Pricing Program.
Daifotis AG. Daifotis AG. JAMA. 2022 Sep 20;328(11):1109. doi: 10.1001/jama.2022.12753. JAMA. 2022. PMID: 36125477 No abstract available.
Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG, Koenig S, Chatenoud L, Herold KC. Daifotis AG, et al. Clin Immunol. 2013 Dec;149(3):268-78. doi: 10.1016/j.clim.2013.05.001. Epub 2013 May 11. Clin Immunol. 2013. PMID: 23726024 Review.
The clinical tolerability profile of alendronate.
Watts N, Freedholm D, Daifotis A. Watts N, et al. Among authors: daifotis a. Int J Clin Pract Suppl. 1999 Apr;101:51-61. Int J Clin Pract Suppl. 1999. PMID: 12669741 Review.
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B. Reginster JY, et al. Among authors: daifotis a. Osteoporos Int. 2006 Jan;17(1):1-7. doi: 10.1007/s00198-005-1984-3. Epub 2005 Aug 10. Osteoporos Int. 2006. PMID: 16091835
Esophagitis associated with the use of alendronate.
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK. de Groen PC, et al. Among authors: daifotis a. N Engl J Med. 1996 Oct 3;335(14):1016-21. doi: 10.1056/NEJM199610033351403. N Engl J Med. 1996. PMID: 8793925 Free article. Review.
27 results